我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

复方鳖甲软肝片对乙肝肝硬化患者PD/PVa比值、Fibroscan和eGFR的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2016年05期
页码:
74-77,89
栏目:
临床研究
出版日期:
2016-10-10

文章信息/Info

Title:
Effect of Fufang Biejia Ruangan Tablets on PD/PVa Fibroscan and eGFR in Treatmentof Patients with Chronic Hepatitis B Cirrhosis
作者:
程贤文1稂慧芳2黄灵跃1曾如雪1傅燕燕1倪伟1施维群1
1. 浙江中医药大学附属第二医院,浙江 杭州 310005;2. 南华大学,湖南 衡阳 421000
Author(s):
CHENG Xianwen1 LANG Huifang2 HUANG Linyue1 ZENG Ruxue1 FU Yanyan1 NI Wei1 SHI Weiqun1
The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China;2. Nanhua University, Hengyang 421000, China
关键词:
复方鳖甲软肝片 门脉高压 乙肝肝硬化 抗病毒 肝纤维化
Keywords:
Fufang Biejia Ruangan tablets portal hypertension hepatitis B Cirrhosis antiviral Liver fibrosis.
分类号:
R256.4
DOI:
10.19288/j.cnki.issn.1000-2723.2016.05.019
文献标识码:
A
摘要:
目的〓观察复方鳖甲软肝片对拉米夫定(贺普丁)联合阿德福韦酯(贺维力)治疗的慢乙肝肝硬化门脉高压患者的临床疗效和安全性。方法〓选94例乙肝肝硬化门脉高压患者,随机分为观察组48例和对照组46例,观察组给予贺维力联合贺普丁(简称双贺)及复方鳖甲软肝片治疗,对照组予“双贺”联合抗病毒治疗。疗程各12个月,观察门静脉主干直径(PD)与门脉血流平均速度(PVa)的比值、肝脏Febroscan(LSM)、FIB4指数、肾小球率过滤(eGFR)、尿蛋白四项、HBVDNA载量、child-pugh量化评分(CTP评分)。结果〓治疗12月后比较,观察组CTP评分及HBADNA载量与对照组比较,差异均无统计学意义(P>0.05);观察组PD/PVa比值与对照组比较,差异有统计学意义(P<0.05);LSM及FIB4改善,观察组较对照组差异有统计学意义(P<0.05);观察组eGFR较对照组改善明显(P<0.05),尿蛋白4项观察组较对照组差异有统计学意义(P<0.05)。结论〓复方鳖甲软肝片对“双贺”治疗的乙肝肝硬化患者通过抗肝纤维化、加快门脉平均血流速度、降低门脉直径等作用改善门静脉血流动力学,同时对患者肾功能有改善作用,临床运用安全性良好,但对肝硬化门脉高压患者的child-pugh评分及病毒载量无显著影响。
Abstract:
Objective To observe the clinical effect and Security of Fufang Biejia Ruangan pills Lamivudine and Adefovir on portal hypertension in patients with liver cirrhosis. Methods The 94 patients with liver cirrhosis portal hypertension, were randomly divided into two groups: the observational group with 35 cases oraling Fufang Bijia Ruangan tablets, Lamivudine and Adefovir, and the control group 33 oraling only antiviral drugs. And the treatment lasted 12 monthes. The message of HBVDNA, PD, PVa, ALT, AST, PLT, LSM, CTP, Serum creatinine and Four urinary protein signs were recorded at baseline, 6th month, 12th month. Results Observational group was statistically significant than the control group in PD/PVa, FIB4, LSM, eGFR, IGU and α1M1(P<0.05). But, in other hands, for example HBVDNA, CTP, TRU and MA, two groups was no significant difference(P>0.05). Conclusion Fufang Bijia Ruangan tablets, being security, can improve Portal hemody namics by lightening Liver Fibrosis, reducing the diameter of portal vein, increasing Portal vein mean velocity, and can protecting the renal function.

参考文献/References

[1] Ott JJ,Stevens GA,Groeger J,et al. Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine,2012,30(12):2212-2219.
[2] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 cause of death for 20 age gropes in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.
[3] 焦念勇,张涵健. 复方鳖甲软肝片联合恩替卡韦治疗乙型肝炎后肝硬化疗效及安全性[J]. Chinese Hepatology,2015,20(5):396-398.
[4] 夏晖,张宁,周双男,等. 复方鳖甲软肝片抗肝纤维化研究进展[J]. Herald of Medicine,2013,32(4):500-502.
[5] 周光德,李文淑,赵景民,等. 复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J]. 解放军医学杂志,2004,29(7):563-564.
[6] 葛钧波,徐永健. 内科学[M]. 8版. 北京. 人民卫生出版社,2013:419-428.
[7] Marcellin P,Chang TT,Lim SG,et al. Long-term efficacy and safty of adefocir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B[J]. Hepatology,2008,48(3):750-758.
[8] 王喜梅. 复方鳖甲软肝片联合西药治疗慢性乙型肝炎150例[J]. 陕西中医,2011,32(7):856-858.
[9] 王晓彬,范晓萍. 替诺福韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床观察[J]. 中国社区医师,2016,32(14):100-102.
[10] 付菊平. 复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化的临床观察[J]. 中国实用医药,2016,11(16):144-146.
[11] Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(S):100-107.
[12] Chan HL,Wong VW,Wong GL,et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. US National Library of Medicine National Institutes of Health. Hepatology. 2010;52(4):1232-1241.
[13] 梁志清,吴建林,吴继周,等. 慢性HBV感染不同临床类型机体免疫对HBsAg和HBV DNA水平的影响. [J]. 江苏医药,2010,36(17):1994-1995.
[14] 中华医学会肝病学分会中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J]. 中华肝脏病杂志,2015,10(1):12-14.
[15] 中华医学会肝病学分会中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志,2005,13(12):881-891.
[16] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指(2010年版)[J]. 中华流行病学杂志,2011,32(4):408-414.
[17] 杨将领,张斌. 92例ALT持续正常的慢性乙型肝炎患者肝组织病理HBV-DNA水平与中医证型相关性分析[J]. 云南中医学院学报,2014,37(6):48-50.

备注/Memo

备注/Memo:
* 基金项目: 中国肝炎防治基金会王宝恩肝纤维化研究基金(Xjs001);浙江省中医药管理局项目(2016ZB005) 收稿日期: 2016 - 08 - 15 作者简介: 程贤文(1988-),男,陕西镇安人,在读硕士研究生,研究方向:感染性疾病的中西医结合治疗。△通信作者:施维群,E-mail:13018900041@126.com
更新日期/Last Update: 2016-10-10